Aberdeen Group plc Acquires 27,107 Shares of Amgen Inc. $AMGN

Aberdeen Group plc lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 629,646 shares of the medical research company’s stock after purchasing an additional 27,107 shares during the quarter. Aberdeen Group plc owned 0.12% of Amgen worth $206,089,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. West Family Investments Inc. grew its holdings in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares in the last quarter. Viawealth LLC increased its position in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd raised its holdings in Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after acquiring an additional 30 shares in the last quarter. Sittner & Nelson LLC boosted its position in Amgen by 0.4% during the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after purchasing an additional 30 shares during the last quarter. Finally, ORG Partners LLC boosted its position in Amgen by 0.6% during the fourth quarter. ORG Partners LLC now owns 5,398 shares of the medical research company’s stock valued at $1,767,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Barclays initiated coverage on Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target on the stock. UBS Group raised their target price on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Wells Fargo & Company increased their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Finally, Citigroup increased their price target on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $354.60.

Amgen Stock Down 1.5%

AMGN opened at $347.94 on Friday. The stock’s fifty day simple moving average is $363.59 and its 200 day simple moving average is $331.85. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The stock has a market cap of $187.56 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 3.50 and a beta of 0.47. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the company earned $5.31 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s dividend payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.